Spotting Alzheimer’s Early: Proactive Care Prevents Up to 40% of Dementia Cases

The narrative surrounding Alzheimer’s disease has long been one of inevitability – a natural part of aging, rather than a medical condition that requires proactive care. This dismissal of early signs is particularly concerning given the staggering statistics: 75% of people living with dementia worldwide remain undiagnosed, and those who do receive a diagnosis often wait up to two years for a proper diagnosis.

Recent research from the Chinese University of Hong Kong has shed light on the prevalence of mild neurocognitive disorder (NCD) among older adults in Hong Kong. The findings are alarming: nearly 22% of people aged 60 and over have some form of NCD, while close to 10% meet criteria for major NCD (dementia). These numbers underscore the need for early detection and systematic risk assessment.

According to Dr. Shea Yat-fung, a geriatrician and dementia specialist, clinicians must prioritize proactive care when diagnosing Alzheimer’s disease. This involves reviewing medical history and using blood tests to identify biomarkers associated with the condition, such as amyloid and tau. While current diagnostic guidelines rely heavily on protein levels in the bloodstream, doctors must also set thresholds for blood tests using statistical methods to ensure high sensitivity and specificity.

The complexity of these diagnostic methods often gets lost in translation. Dr. Yat-fung notes that doctors must carefully assess the results, with values above an upper cut-off considered positive and those below a lower cut-off considered negative. The “grey zone” – where results fall between the two cut-offs – requires further follow-up.

The availability of diagnostic tools is another pressing concern. Amyloid PET scans, for example, are costly and limited in availability in Hong Kong, with costs running into tens of thousands of dollars per patient. These financial barriers create a significant obstacle for patients who may require definitive diagnoses to access new treatments.

The reliance on biomarkers raises questions about our understanding of Alzheimer’s disease. Are we simply treating symptoms, or are we truly addressing the underlying causes? The medical community is divided on this issue, with some arguing that biomarker testing is a necessary step towards diagnosis and treatment, while others contend that it oversimplifies the complexities of the human brain.

As researchers continue to advance our understanding of Alzheimer’s disease, it’s essential to prioritize early detection and proactive care. This requires not only advances in diagnostic technology but also systemic changes within healthcare systems. By investing in timely screening and risk assessment, we can reduce downstream care burdens and improve outcomes for patients.

The current state of affairs is a stark reminder that Alzheimer’s disease is not an inevitable part of aging. Rather, it’s a medical condition that requires proactive attention and care. By changing our narrative around this disease, we can begin to address the pressing public-health concern that cognitive health poses – especially among older adults.

Early detection and systematic risk assessment are essential to slowing progression and preserving function. Studies suggest that up to 40% of dementia cases could be prevented with timely screening and proactive care. For patients and their families, this means reducing wait times and increasing access to diagnostic tools, which can have a profound impact on quality of life.

The road ahead will undoubtedly be complex, with challenges ranging from healthcare system reform to advances in diagnostic technology. However, one thing is clear: it’s time to rewrite the narrative surrounding Alzheimer’s disease. By prioritizing proactive care, we can begin to close gaps and provide better support for those affected by this debilitating condition.